Abstract: A system and method for driveway marker light safety system mainly to assist the snowplow drivers during adverse weather conditions is disclosed. The lighting marker system comprises a set of telescoping tubes positioned on either side of the driveway wherein it has extending sections along with a light fixture placed on top of the apparatus. The system further comprises a photo eye detector for detecting the snow obstruction and adjusts the marker light section by using a gear drive or coiled plastic rod mechanism. A solar panel is provided in the apparatus for supporting the power supply.

Abstract: An integrated jacking system includes built-in jacks for each wheel of the vehicle. Electric motor-driven screw or worm-gear jacks are welded to the vehicle frame or unibody aft of the front wheels and forward of the rear wheels. The four jack screws each terminate on the lower end in a rotatable ball-jointed footing adaptable to uneven drive surfaces beneath the vehicle wheels. The integrated jacking system is controlled by the vehicle computer through a passcode-accessible central jacking control interface. The vehicle computer is programmed to implement safety protocols: allowing only one wheel at a time to be jacked up, limiting jacking height of a wheel to not more than six inches (6?) off the ground, and disabling the jacking system if the grade of the underlying surface exceeds twenty percent (20%) or if the parking brake is not set.

Abstract: The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.

Abstract: The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.